Nabriva Therapeutics PLC (NBRVF)

[cash_cow1]

Continuing large insiders buying being filed with the SEC. Plus Nabriva Therapeutics to present Lefamulin Topline Phase III late stage data result at the Jefferies Global Healthcare conference in New York City June 5 and 6 and present at the ASM Microbiology June 7 to 11th. should get a very nice share price increase from $4 to over $9 after the positive topline data on Lefamulin late clinical trial III study with a high positive endpoint to support clinical trial that Lefamulin tx bacterial pneumonia infection in 5 days compare to Moxifloxacin 7 days treatment.

Lefamulin proven non inferior to Moxifloxacin. Company is expected to file for a New Drug Application (NDA) to the FDA. Presentations at each of the Healthcare conference will show the new positive data results of the late stage clinical trial study phase III. Large insiders buying shows company has high support and believe in the clinical trial studies of Lefamulin and that it will be approve by the FDA.